A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses

被引：25

作者：

Bogani, Giorgio ^{[1
]}

Tagliabue, Elena ^{[1
]}

Signorelli, Mauro ^{[1
]}

Ditto, Antonino ^{[1
]}

Martinelli, Fabio ^{[1
]}

Chiappa, Valentina ^{[1
]}

Mosca, Lavinia ^{[1
]}

Sabatucci, Ilaria ^{[1
]}

Maggiore, Umberto Leone Roberti ^{[1
]}

Lorusso, Domenica ^{[1
]}

Raspagliesi, Francesco ^{[1
]}

机构：

[1] IRCCS Natl Canc Inst, Dept Gynecol Oncol, Via Venezian 1, I-20133 Milan, Italy

来源：

JOURNAL OF GYNECOLOGIC ONCOLOGY | 2018年 / 29卷 / 03期

关键词：

Ovarian Neoplasms; Recurrence; Cytoreduction Surgical Procedures; EPITHELIAL OVARIAN; SURVIVAL; VALIDATION; CRITERIA; MODELS;

D O I：

10.3802/jgo.2018.29.e40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To test the applicability of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC). Methods: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynakologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS. Results: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857). Conclusion: The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.

引用

页数：11

共 22 条

[21] External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer [J].

van de laar, Rafli ;

Massuger, Leon. F. A. G. ;

Van Gorp, Toon ;

IntHout, Joanna ;

Zusterzeel, Petra. L. M. ;

Kruitwagen, Roy. F. P. M. .

GYNECOLOGIC ONCOLOGY, 2015, 137 (02) :210-215

[22] Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum- sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study [J].

van de laar, Rafli ;

Zusterzeel, Petra L. M. ;

Van Gorp, Toon ;

Buist, Marrije R. ;

van Driel, Willemien J. ;

Gaarenstroom, Katja N. ;

Arts, Henriette J. G. ;

van Huisseling, Johannes C. M. ;

Hermans, Ralph H. M. ;

Pijnenborg, Johanna M. A. ;

Schutter, Eltjo M. J. ;

Pelikan, Harold M. P. ;

Vollebergh, Jos H. A. ;

Engelen, Mirjam J. A. ;

IntHout, Joanna ;

Kruitwagen, Roy F. P. M. ;

Massuger, Leon F. A. G. .

BMC CANCER, 2014, 14

← 1 2 3 →